Catamaran supports the hepatitis C drug harvoni of Gilead

Source: Ding Xiangyuan, February 3, 2015, catamaran, a pharmaceutical interest management company, expressed support for harvoni and sovaldi of Gilead science company as the exclusive two hepatitis C drugs and added them to the drug list The company launched a competitive product called viekera at the end of last year The high cure rate for hepatitis C is similar to that of Gilead's drugs Since then, Gilead has reached a series of transactions with drug interest management companies and insurance companies at an amazing speed This agreement makes catamaran one of the broad taxpayer groups that choose Gilead hepatitis C drugs first or exclusively, including Aetna and United Health Group Co., Ltd Catamaran said the agreement was based on clinical efficacy, with data provided by briovarx, a professional pharmacy The company said patients using the drug treatment program will be fully monitored The company declined to provide any information about the protocol's architecture, saying the protocol would guarantee that the cost-effective drug would provide its intended efficacy Harvoni is a combination containing sovaldi, which is priced at $94500, while sovaldi alone costs $84000 per course Aberdeen's drug is multiple pills in eye blister packaging that can be taken daily and is priced at $83319 Analysts and investors estimate that the price war between Aberdeen and Gilead will lead to a discount on drug prices and a rebate of around 30%, but both declined to comment on the figures